Incidence of clinical symptoms in ChAglyCD3-treated patients at the time of EBV reactivation as compared with placebo-treated patients in whom no EBV reactivation was observed
| Severity . | ChAglyCD3 . | Placebo . | ||||
|---|---|---|---|---|---|---|
| Mild (grade 1) . | Moderate (grade 2) . | Severe (grade 3) . | Mild (grade 1) . | Moderate (grade 2) . | Severe (grade 3) . | |
| Hyperthermia | 7 | 4 | 1 | 0 | 1 | 0 |
| Cervical lymph node enlargement | 2 | 7 | 1 | 3 | 0 | 0 |
| Sore throat | 13 | 15 | 1 | 1 | 2 | 0 |
| Severity . | ChAglyCD3 . | Placebo . | ||||
|---|---|---|---|---|---|---|
| Mild (grade 1) . | Moderate (grade 2) . | Severe (grade 3) . | Mild (grade 1) . | Moderate (grade 2) . | Severe (grade 3) . | |
| Hyperthermia | 7 | 4 | 1 | 0 | 1 | 0 |
| Cervical lymph node enlargement | 2 | 7 | 1 | 3 | 0 | 0 |
| Sore throat | 13 | 15 | 1 | 1 | 2 | 0 |
Symptoms were scored as mild, moderate, or severe according to the Common Terminology Criteria for adverse events, Version 3.0, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Department of Health and Human Services (March 31, 2003; http://ctep.cancer.gov), August 9, 2006. Grades refer to the severity of the adverse event and range from 1 to 5. None of the patients in this study experienced an adverse event of grade 4 (life threatening or disabling). Mild symptoms were spontaneously reversible (no treatment), and only symptomatic treatment was applied, when needed, in case of moderate symptoms.